六味能消胶囊联合脂必泰胶囊治疗高脂血症的临床研究

目的探讨六味能消胶囊联合脂必泰胶囊治疗高脂血症的临床效果。方法选取2017年5月—2018年10月东营市东营区人民医院收治的64例高脂血症患者,随机分为对照组和治疗组,每组各32例。对照组口服脂必泰胶囊,1粒/次,2次/d。治疗组在对照组治疗基础上口服六味能消胶囊,1粒/次,3次/d。两组均连续治疗8周。观察两组的临床疗效,比较两组治疗前后血脂指标、血流变学指标、血小板参数及血清学指标的变化情况。结果治疗后,对照组和治疗组的总有效率分别是75.0%、96.9%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组总胆固醇(TC)、非-HDL-C、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)水平均较治疗前显著降低,而高密度脂蛋白胆固醇(HDL-C)显著升高,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组TC、非-HDL-C、TG、LDL-C水平低于对照组,而HDL-C高于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组血浆黏度(PV)、红细胞比容(HCT)、聚集指数(RCAI)、平均血小板体积(MPV)、血小板最大聚集率(MAR)均显著降低,而变形指数(RDI)值均显著升高,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,PV、HCT、RCAI、MPV、MAR值均显著低于对照组,而RDI值高于对照组,两组比较差异具有统计学意义(P<0.05)。治疗后,两组血清C反应蛋白(CRP)、内皮素(ET)水平较治疗前均显著降低,而一氧化氮(NO)水平显著增高,同组治疗前后比较差异具有统计学意义(P<0.05);治疗后,治疗组CRP、ET水平低于对照组,而NO水平高于对照组,两组比较差异有统计学意义(P<0.05)。结论六味能消胶囊联合脂必泰胶囊治疗高脂血症具有较好的临床疗效,综合调脂作用显著,可明显纠正患者体内血流变学异常,改善血小板功能及微炎症状态,保护血管内皮功能,具有一定的临床推广应用价值。

Clinical study on Liuwei Nengwei Capsules combined with Zhibitai Capsules in treatment of hyperlipidemia

Objective To investigate the clinical effect of Liuwei Nengwei Capsules combined with Zhibitai Capsules in treatment of hyperlipidemia. Methods Patients (64 cases) with hyperlipidemia in the People''s Hospital of Dongying District in Dongying City from May 2017 to October 2018 were randomly divided into control (32 cases) and treatment (32 cases) groups. Patients in the control group were po administered with Zhibitai Capsules, 1 grain/time, twice daily. Patients in the treatment group were po administered with Liuwei Nengwei Capsules on the basis of the control group, 1 grain/time, three times daily. Patients in two groups were treated for 8 weeks. After treatment, the clinical efficacy was evaluated, and the changes of blood lipid indexes, hemorheology indexes, platelet parameters and serology indexes in two groups before and after treatment were compared. Results After treatment, the clinical efficacy in the control and treatment groups were 75.0% and 96.9%, respectively, and there were differences between two groups (P < 0.05). After treatment, TC, non-HDL-C, TG, and LDL-C in two groups were significantly decreased, but HDL-C was significantly increased, and there were differences in the same group (P < 0.05). After treatment, TC, non-HDL-C, TG, and LDL-C in the treatment group were lower than those in the control group, but HDL-C was higher than that in the control group, and there were differences between two groups (P < 0.05). After treatment, PV, HCT, RCAI, MPV, and MAR in two groups were significantly decreased, but RDI was significantly increased, and there were differences in the same group (P < 0.05). After treatment, PV, HCT, RCAI, MPV, and MAR in the treatment group were lower than those in the control group, but RDI was higher than that in the control group, and there were differences between two groups (P < 0.05). After treatment, CRP and ET in two groups were significantly decreased, but NO was significantly increased, and there were differences in the same group (P < 0.05). After treatment, CRP and ET in the treatment group were lower than those in the control group, but NO was higher than that in the control group, and there were differences between two groups (P < 0.05). Conclusion Liuwei Nengwei Capsules combined with Zhibitai Capsules has significant effect in treatment of hyperlipidemia, and comprehensive lipid-regulating effect is significant, and can significantly correct the hemorheological abnormalities, also can improve platelet function and microinflammatory state, and protect vascular endothelial function, which has a certain clinical application value.